CN114650823A - 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物 - Google Patents

用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物 Download PDF

Info

Publication number
CN114650823A
CN114650823A CN202080058522.0A CN202080058522A CN114650823A CN 114650823 A CN114650823 A CN 114650823A CN 202080058522 A CN202080058522 A CN 202080058522A CN 114650823 A CN114650823 A CN 114650823A
Authority
CN
China
Prior art keywords
flt3
pharmaceutical composition
amino
hydroxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058522.0A
Other languages
English (en)
Chinese (zh)
Inventor
裵仁焕
宋芝英
崔载律
安永吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CN114650823A publication Critical patent/CN114650823A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080058522.0A 2019-06-27 2020-06-25 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物 Pending CN114650823A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0077302 2019-06-27
KR20190077302 2019-06-27
PCT/KR2020/008258 WO2020262974A1 (ko) 2019-06-27 2020-06-25 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
CN114650823A true CN114650823A (zh) 2022-06-21

Family

ID=74060307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058522.0A Pending CN114650823A (zh) 2019-06-27 2020-06-25 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物

Country Status (11)

Country Link
US (1) US12350265B2 (https=)
EP (1) EP3991733A4 (https=)
JP (1) JP2022538817A (https=)
KR (1) KR20210002015A (https=)
CN (1) CN114650823A (https=)
AU (1) AU2020308814A1 (https=)
CA (1) CA3145391A1 (https=)
EA (1) EA202290154A1 (https=)
IL (1) IL289366A (https=)
MX (1) MX2021015724A (https=)
WO (1) WO2020262974A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
TW202246243A (zh) * 2021-02-26 2022-12-01 美商泰拉生物科學公司 胺基嘧啶化合物及其使用方法
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2024206989A2 (en) * 2023-03-30 2024-10-03 Bioventures, Llc Flt3 inhibitors and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622015A (zh) * 2007-03-05 2010-01-06 协和发酵麒麟株式会社 药物组合物
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2007325280B2 (en) 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
UY32203A (es) 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
CA2755976C (en) * 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
WO2014155300A2 (en) 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
CN106458969A (zh) 2014-08-25 2017-02-22 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
KR101799781B1 (ko) 2015-07-23 2017-11-22 재단법인 강릉과학산업진흥원 소뼈 추출분말의 제조방법
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102110573B1 (ko) 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
AU2016324920B2 (en) 2015-09-14 2022-03-03 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
US10927418B2 (en) 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
CA3018155A1 (en) 2016-03-29 2017-10-05 Astellas Pharma Inc. Combination therapy for the treatment of acute myeloid leukemia
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
US20200039998A1 (en) 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
ES2938648T3 (es) 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
EP3789386A1 (en) 2017-01-26 2021-03-10 Hanmi Pharm. Co., Ltd. Pyrimidine compound and pharmaceutical use thereof
TWI821174B (zh) 2017-02-21 2023-11-11 加拿大商艾普托斯生物科學公司 治療血液惡性腫瘤患者的方法
EP3661511A1 (en) 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
EP3755703B1 (en) 2018-02-20 2022-05-04 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
KR102297587B1 (ko) 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
BR112021016522A2 (pt) * 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
KR20210038366A (ko) 2019-09-30 2021-04-07 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN115151534B (zh) 2020-02-14 2024-02-06 南京药石科技股份有限公司 白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
EP4241773A4 (en) 2020-11-05 2024-10-16 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR
KR20230056331A (ko) 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
AU2023372170A1 (en) 2022-11-04 2025-04-24 Hanmi Pharm. Co., Ltd. Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof
WO2024124199A1 (en) 2022-12-10 2024-06-13 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
CN121586574A (zh) 2023-05-31 2026-02-27 韩美药品株式会社 髓样激酶组抑制剂的固体分散体和包含所述固体分散体的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622015A (zh) * 2007-03-05 2010-01-06 协和发酵麒麟株式会社 药物组合物
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOKO UENO等: "Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia", ONCOTARGET, vol. 10, no. 26, XP002809353 *

Also Published As

Publication number Publication date
KR20210002015A (ko) 2021-01-06
EP3991733A1 (en) 2022-05-04
EA202290154A1 (ru) 2022-03-29
MX2021015724A (es) 2022-05-16
WO2020262974A1 (ko) 2020-12-30
AU2020308814A1 (en) 2022-02-03
CA3145391A1 (en) 2020-12-30
IL289366A (en) 2022-02-01
US20220354842A1 (en) 2022-11-10
JP2022538817A (ja) 2022-09-06
US12350265B2 (en) 2025-07-08
EP3991733A4 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
CN114650823A (zh) 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物
KR101781654B1 (ko) 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
JP2023182577A (ja) 化学療法計画中の免疫応答の保護
Robak et al. Current and emerging treatments for chronic lymphocytic leukaemia
CN106860870B (zh) 抗肿瘤生物碱的联合治疗
JP7577672B2 (ja) Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
CN109641002B (zh) 血液癌症的组合治疗
CN104116738A (zh) 癌症的治疗
CN102753176B (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
CN113490497B (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
TW202425991A (zh) 阿森色替於治療癌症中之間歇性給藥方案
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
JP2023533489A (ja) 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用
KR20210038366A (ko) Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN118510517A (zh) 用于治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合
TWI777321B (zh) 藥物組合及其用途
HK40063890A (en) Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
JP2023061488A (ja) 組み合わせ医薬として用いられるメニン－ｍｌｌ阻害剤を含有する医薬組成物
HK40066212A (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
JP2026510567A (ja) 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
HK40111044A (zh) 用於治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合
CN113797342A (zh) 用于预防或治疗肿瘤疾病的治疗剂组合
MX2008000894A (en) Compositions for treatment of systemic mastocytosis
HK1220121B (zh) 取代的2，3-二氢咪唑并[1，2-c]喹唑啉治疗淋巴瘤的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220621

WD01 Invention patent application deemed withdrawn after publication